Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of AZD2389 Alone and with Quinidine
NCT06974565Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AZD2389 in advanced chronic liver disease (ACLD) (2 arms), sponsored by AstraZeneca. Primary endpoints: Ratio of Maximum Observed Plasma Concentration, Ratio of Area Under Concentration-Time Curve from Time 0 to Infinity and 1 more. Started May 2025; status: completed.
02
Drugs
AZD2389
03
Conditions
advanced chronic liver disease (ACLD)
Beyond the preview
Go deeper on NCT06974565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06974565.